MorphoSys Stock Falls After Trimming Upper End Of 2021 Revenue Outlook

  • MorphoSys AG MOR expects group revenues of €155 million to €180 million (previously: €150 to € 200 million, provided on March 15 and reiterated on May 5, 2021). 
  • The updated revenue guidance primarily reflects updated Monjuvi product sales expectations.
  • MorphoSys now expects operating expenses of €435 million to € 465 million (previously €355 to € 385million). 
  • R&D expenses now are expected to comprise 52 to 57% of Group operating expenses (previously 45-50%), excluding one-time transaction-related costs. 
  • The updated guidance for operating expenses mainly reflects the acquisition of Constellation Pharmaceuticals.
  • The revised numbers also include one-time transaction costs of €36 million.
  • As a result of the updated Monjuvi product sales expectations, the balance sheet position "financial liabilities from collaborations, net of current portion" is reduced from €547.6 million to €445.9 million.
  • Full results will be published as planned on July 28.
  • Price Action: MOR shares are down 5% at $15.37 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechEarningsM&ANewsGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!